

**Egypt Anti-Hypertensive Drugs Market, By Therapeutic Class (Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores), By Region, Competition Forecast & Opportunities, 2028**

Market Report (3 business days) | 2023-10-03 | 89 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

**Report description:**

The market for anti-hypertensive drugs in Egypt is expected to expand at an incredible pace between 2024 and 2028. Many people across the world suffer with hypertension, also known as high blood pressure. A significant percentage of the population in Egypt suffers from hypertension, which is an important contributor to heart attacks and strokes as well as other cardiovascular conditions. The market for anti-hypertensive drugs has expanded as a result of unhealthy lifestyle choices such as smoking, improper eating, and a lack of physical activity.

Generic anti-hypertensive drugs are becoming more widely available in Egypt, making it simpler and more economical for patients to get their medications. As a result, there is a greater need for anti-hypertensive drugs, which has helped the market grow. New and more effective anti-hypertensive drugs have been created as a result of advances in technology in the field of medicines. Due to the rise in the demand for more advanced as well as effective treatments, the availability of these drugs has helped the market expand.

Patients from all over the world seeking to take advantage of affordable healthcare services visit Egypt, which continues to be an important destination for medical tourism. The availability of anti-hypertensive drugs and other medications has led to the expansion of the medical tourism sector in Egypt, which has supported the market to grow.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Increased access to health insurance in Egypt has rendered it simpler for patients to obtain healthcare services, such as anti-hypertensive drugs. As a result, there is more demand for these drugs, which has helped the market grow. The Egyptian government has been spending more on healthcare lately which has helped the market expansion. Spending higher amounts has ended up resulting in new healthcare facilities being developed, more people having access to healthcare services, and more people needing anti-hypertensive drugs.

According to an article titled "A semi-systematic review on hypertension and dyslipidemia care in Egypt-highlighting evidence gaps and recommendations for better patient outcomes", the prevalence of hypertension in Egypt ranged from 12.1 to 59%. Many barriers hinder the growth of the market for anti-hypertensive drugs in Egypt. Factors such as the high cost of medications, low awareness of hypertension, inadequate healthcare infrastructure, lenient regulatory framework, lack of qualified professionals, resistance to change, insufficient funding, insufficient insurance coverage, dependence on imports, and lack of proper monitoring are a few challenges that may hinder the growth of the Egypt anti-hypertensive drugs.

Egypt's inadequate healthcare system has an impact on the market expansion for anti-hypertensive medications. There is a lack of medical staff, supplies, and facilities, which leads to substandard healthcare services, especially the accessibility of anti-hypertensive medications.

The healthcare industry in Egypt has a shortage in skilled professionals. This has an impact on the quality of healthcare services and the expansion of the market for anti-hypertensive drugs. Many healthcare providers lack the abilities and information necessary to correctly identify and manage hypertension.

Despite the availability of generic anti-hypertensive drugs, the cost of medication is still a major barrier for many people in Egypt. The high cost of treatment can prevent patients from accessing the medication they need, resulting in untreated or poorly managed hypertension. This affordability issue is especially challenging for those without health insurance or those living in rural areas where access to healthcare services is limited.

The Egyptian government has been placing a growing emphasis on prevention and early detection of hypertension. This includes initiatives such as public awareness campaigns, screening programs, and training programs for healthcare professionals. By promoting prevention and early detection, the government aims to reduce the burden of hypertension and its associated complications. This focus on prevention and early detection is expected to drive the demand for anti-hypertensive drugs, which, in turn, will support the growth of the market in the coming years.

Combination therapies, which involve the use of two or more drugs to manage hypertension, are becoming increasingly popular in Egypt. Combination therapies are often more effective than single-drug therapies and can help patients achieve their blood pressure goals more quickly. The increasing use of combination therapies is expected to drive the demand for anti-hypertensive drugs, which, in turn, will support the growth of the market in the coming years.

Telemedicine, which involves the use of remote communication technologies to provide healthcare services, is becoming increasingly popular in Egypt. Telemedicine can help overcome the challenges of inadequate healthcare infrastructure and shortages of healthcare professionals, particularly in rural areas. The increasing adoption of telemedicine is expected to increase access to healthcare services, which, in turn, will drive the demand for anti-hypertensive drugs in the coming years.

**Rising Prevalence of Hypertension**

The growing prevalence of hypertension in Egypt can be attributed to several factors, including an aging population, changing dietary patterns, and sedentary lifestyles. As the population continues to age and adopt unhealthy lifestyles, the prevalence of hypertension is expected to increase further. This has led to a growing demand for antihypertensive drugs in Egypt, which is expected to drive the growth of the market in the coming years.

Antihypertensive drugs work by reducing blood pressure and preventing damage to the organs that can be caused by high blood pressure. There are several classes of antihypertensive drugs available in Egypt, including diuretics, beta-blockers, ACE inhibitors, calcium channel blockers, and angiotensin receptor blockers. These drugs are often used in combination to achieve blood pressure control.

The growing prevalence of hypertension in Egypt has led to an increased demand for antihypertensive drugs, which, in turn, has increased the availability and affordability of these drugs. As the market for antihypertensive drugs in Egypt continues to grow, there has been a focus on improving access to these drugs, particularly in rural areas.

**Technological Advancements**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Technological advancements have a significant impact on the growth of the Egypt anti-hypertensive drugs market. These advancements have enabled the development of new drugs, improved drug delivery methods, and enhanced patient monitoring and management systems, among other things. As a result, technological advancements have facilitated the growth of the Egypt anti-hypertensive drugs market in several ways.

The use of technology has also enabled the development of more effective drug delivery methods. For example, advances in nanotechnology have enabled the development of nanocarriers, which can be used to deliver drugs directly to target cells or tissues. This approach can improve drug efficacy while reducing side effects.

In addition to drug development and delivery, technological advancements have facilitated the development of patient monitoring and management systems. Wearable devices, such as smartwatches and fitness trackers, can monitor blood pressure and other vital signs and provide real-time feedback to patients and healthcare providers. This can help patients to better manage their hypertension and can enable healthcare providers to provide more personalized and effective care.

Advancements in telemedicine and remote monitoring technologies have enabled patients in remote or underserved areas to receive medical care for hypertension. This has helped to improve access to care and to reduce the burden of hypertension on the healthcare system.

#### Introduction of Telemedicine

Telemedicine has the potential to revolutionize the way that healthcare is delivered in Egypt, and this is particularly true for the treatment of hypertension. As telemedicine continues to grow and become more widely adopted, it is expected to have a significant impact on the growth of the anti-hypertensive drugs market in Egypt.

Telemedicine can also help to improve medication adherence among patients with hypertension. Studies have shown that patients who receive remote monitoring and support are more likely to take their medications as prescribed and to make lifestyle changes that can help to control their hypertension. This can lead to better health outcomes and a reduced risk of complications associated with hypertension.

Telemedicine can improve patient education and support. Patients with hypertension often require ongoing education and support to manage their condition effectively. Telemedicine platforms can provide patients with access to educational materials, medication reminders, and personalized coaching, among other things. This can help to improve medication adherence and to reduce the risk of complications associated with hypertension.

#### Market Segmentation

The Egypt anti-hypertensive drugs market can be segmented by therapeutic class, type, distribution channel, and region. By therapeutic class, the Egypt anti-hypertensive drugs market can be segmented into diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, beta adrenergic blockers, renin inhibitors, vasodilators, and others. Based on type, the Egypt anti-hypertensive drugs market is further segmented into primary hypertension and secondary hypertension. Based on distribution channel, the Egypt anti-hypertensive drugs market is further segmented into retail pharmacy, hospital pharmacy, and e-commerce websites & online drug stores.

#### Market Players

Amoun Pharmaceutical Company, EIPICO (Egyptian International Pharmaceutical Industries Co.), Delta Pharma, Rameda Pharmaceutical Company, El-Nasr Pharmaceutical Chemicals Company, and Egyphar are some of the leading companies operating in the market.

#### Report Scope:

In this report, the Egypt anti-hypertensive drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

##### □□Egypt Anti-Hypertensive Drugs Market, By Therapeutic Class

##### o□Diuretics

##### o□ACE inhibitors

##### o□Angiotensin Receptor Blockers (ARBs)

##### o□Calcium Channel Blockers

##### o□Beta Adrenergic Blockers

##### o□Renin Inhibitors

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- o Vasodilators
- o Others
- Egypt Anti-Hypertensive Drugs Market, By Type
  - o Primary Hypertension
  - o Secondary Hypertension
- Egypt Anti-Hypertensive Drugs Market, By Distribution Channel
  - o Retail Pharmacy
  - o Hospital Pharmacy
  - o E-commerce Websites & Online Drug Stores
- Egypt Hospital Bed Market, By Region
  - o Cairo
  - o Alexandria
  - o Giza Qalyubia
  - o Port Said Suez
  - o Rest of Egypt

#### Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Egypt anti-hypertensive drugs market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

#### Table of Contents:

1. Product Overview
  - 1.1. Market Definition
  - 1.2. Scope of the Market
    - 1.2.1. Markets Covered
    - 1.2.2. Years Considered for Study
    - 1.2.3. Key Market Segmentations
2. Research Methodology
  - 2.1. Objective of the Study
  - 2.2. Baseline Methodology
  - 2.3. Key Industry Partners
  - 2.4. Major Association and Secondary Types
  - 2.5. Forecasting Methodology
  - 2.6. Data Triangulation & Validation
  - 2.7. Assumptions and Limitations
3. Executive Summary
  - 3.1. Overview of the Market
  - 3.2. Overview of Key Market Segmentations
  - 3.3. Overview of Key Market Players
  - 3.4. Overview of Key Regions/Countries
  - 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Egypt Anti-Hypertensive Drugs Market Outlook

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.□Market Size & Forecast
  - 5.1.1.□By Value
- 5.2.□Market Share & Forecast
  - 5.2.1.□By Therapeutic Class (Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others)
  - 5.2.2.□By Type (Primary Hypertension, Secondary Hypertension)
  - 5.2.3.□By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores)
  - 5.2.4.□By Region (Cairo, Qalyubia, Alexandria, Port Said, Giza, Suez)
  - 5.2.5.□By Company (2022)
- 5.3.□Product Market Map
  - 5.3.1.□By Therapeutic Class
  - 5.3.2.□By Type
  - 5.3.3.□By Distribution Channel
  - 5.3.4.□By Region
- 6.□Cairo Anti-Hypertensive Drugs Market Outlook
  - 6.1.□Market Size & Forecast□
    - 6.1.1.□By Value
  - 6.2.□Market Share & Forecast
    - 6.2.1.□By Therapeutic Class
    - 6.2.2.□By Type
    - 6.2.3.□By Distribution Channel
- 7.□Qalyubia Anti-Hypertensive Drugs Market Outlook
  - 7.1.□Market Size & Forecast□
    - 7.1.1.□By Value
  - 7.2.□Market Share & Forecast
    - 7.2.1.□By Therapeutic Class
    - 7.2.2.□By Type
    - 7.2.3.□By Distribution Channel
- 8.□Alexandria Anti-Hypertensive Drugs Market Outlook
  - 8.1.□Market Size & Forecast□
    - 8.1.1.□By Value
  - 8.2.□Market Share & Forecast
    - 8.2.1.□By Therapeutic Class
    - 8.2.2.□By Type
    - 8.2.3.□By Distribution Channel
- 9.□Port Said Anti-Hypertensive Drugs Market Outlook
  - 9.1.□Market Size & Forecast□
    - 9.1.1.□By Value
  - 9.2.□Market Share & Forecast
    - 9.2.1.□By Therapeutic Class
    - 9.2.2.□By Type
    - 9.2.3.□By Distribution Channel
- 10.□Giza Anti-Hypertensive Drugs Market Outlook
  - 10.1.□Market Size & Forecast□
    - 10.1.1.□By Value
  - 10.2.□Market Share & Forecast
    - 10.2.1.□By Therapeutic Class

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.2. By Type
- 10.2.3. By Distribution Channel
- 11. Suez Anti-Hypertensive Drugs Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value
- 11.2. Market Share & Forecast
- 11.2.1. By Therapeutic Class
- 11.2.2. By Type
- 11.2.3. By Distribution Channel
- 12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
- 13. Market Trends & Developments
- 13.1. Merger & Acquisition
- 13.2. Product Development
- 13.3. Recent Developments
- 14. Policy & Regulatory Landscape
- 15. Egypt Economic Profile
- 16. Competitive Landscape
- 16.1. Business Overview
- 16.2. Company Snapshot
- 16.3. Products & Services
- 16.4. Financials (As Reported)
- 16.5. Recent Developments
- 16.5.1. Amoun Pharmaceutical Company
- 16.5.2. EIPICO (Egyptian International Pharmaceutical Industries Co.)
- 16.5.3. Delta Pharma
- 16.5.4. Rameda Pharmaceutical Company
- 16.5.5. El-Nasr Pharmaceutical Chemicals Company
- 16.5.6. Egyphar
- 17. Strategic Recommendations
- About Us & Disclaimer

**Egypt Anti-Hypertensive Drugs Market, By Therapeutic Class (Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores), By Region, Competition Forecast & Opportunities, 2028**

Market Report (3 business days) | 2023-10-03 | 89 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-04"/>
		Signature	<input type="text"/>